First EFIC® Symposium Societal Impact of Pain - SIP

68
Marja R. Kuijpers
Marja R. Kuijpers
pharmacist, advisor Dutch Health Care
Insurance Board (CVZ)
For the past five years she has been intensively
working on policy aspects of treatment with,
and reimbursement of, expensive medicines.
On behalf of CVZ she initiated the development
of the procedure of assessing expensive
medicines, in order to be able to advise the
Dutch Health Authority (NZa) on payment for
expensive and orphan drugs in hospitals. She
has been involved in a project which has striven
to develop guidelines for observational
research (outcome research) for innovative,
expensive medicines. For the past two years
she has, on behalf of CVZ, directed research
on off-label use of innovative, expensive
medicines, especially oncolytics. On the basis
of the results she wrote a policy report about
off-label use of medicines from the
reimbursement perspective. She was editor of
the Medical Aids Compass of CVZ (list of
reimbursed medical aids, 5 volumes published
between 2002-2005). She is currently
working on a CVZ report on off-label use of
medicines from the perspective of health care
insurance.